Hepatitis B e antibody (anti-HBe)

Hepatitis B e antibody (anti-HBe) is an immunoglobulin produced by the host immune system in response to the Hepatitis B e antigen (HBeAg) during an infection with the Hepatitis B virus (HBV) (StatPearls, 2023). The appearance of anti-HBe in the blood, a process known as seroconversion, typically signifies a transition from a state of high viral replication to a state of low replication (Mayo Clinic Laboratories, 2024). This transition is often associated with a reduction in serum HBV DNA levels and a decrease in the risk of long-term complications such as cirrhosis and hepatocellular carcinoma (CDC, 2023). In clinical management, anti-HBe serves as a vital diagnostic biomarker to determine the phase of HBV infection and to evaluate the patient's immune response to the virus (WHO, 2024). Anti-HBe is also used as a secondary endpoint in clinical trials for antiviral therapies, where the loss of HBeAg and the gain of anti-HBe indicate a favorable treatment outcome (NIH, 2023). However, anti-HBe is not a therapeutic target that drugs are designed to bind to or modulate; instead, it is a product of the body's natural defense mechanism. It is important to note that some patients may develop "e-antigen negative" chronic hepatitis due to viral mutations, where anti-HBe is present despite ongoing high viral replication (PubMed, 2022). Therefore, while anti-HBe is a marker of relative viral suppression, it does not indicate complete eradication of the virus from the host.

Other names

Antibody to Hepatitis B e antigenHBeAbanti-HBeAgHepatitis B virus e antibody

Not applicable; anti-HBe is a host-produced diagnostic biomarker and not a therapeutic target for pharmacological intervention.